crizotinib and Lichen-Planus

Crizotinib was approved by the US Food and Drug Administration in 2011 for the treatment of anaplastic lymphoma kinase (ALK)- or ROS1-positive non-small cell lung cancer (NSCLC). Since then, the number of indicated uses for crizotinib has substantially increased. However, the administration of crizotinib can be associated with various adverse events. It is important that clinicians identify adverse cutaneous manifestations of crizotinib and are aware of their outcomes and treatments to avoid unnecessarily discontinuing a potentially life-saving medication. We describe a case of lichenoid drug eruption (LDE) that appeared 4 weeks after initiation of treatment with crizotinib in a 61-year-old man with ALK-positive metastatic lung adenocarcinoma.

Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Eruptions; Humans; Lichen Planus; Lung Neoplasms; Male; Middle Aged